research use only

Denifanstat (TVB-2640) Fatty Acid Synthase inhibitor

Name: Denifanstat (TVB-2640)
Brand: Selleck Chemicals
SKU: S9714
Availability: InStock
Rating: 5 (9 reviews)

Cat.No.S9714

Denifanstat (TVB-2640) is an orally bioavailable, pharmacological fatty acid synthase (FAS/FASN) inhibitor with therapeutic potential in patients with NAFLD and nonalcoholic steatohepatitis.

Chemical Structure

Molecular Weight: 439.55

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	P450 (e.g. CYP17) Dehydrogenase PDE phosphatase PPAR HSP Vitamin Transferase Carbohydrate Metabolism Mitochondrial Metabolism Drug Metabolite Casein Kinase Serine/threonin kinase Lipoxygenase LPL Receptor Phospholipase (e.g. PLA) Retinoid Receptor DPP ACE Peroxidases Amino Acids and Derivatives Glucokinase FXR HMG-CoA Reductase Carbonic Anhydrase Lipase Decarboxylase DHFR IDO/TDO Hydroxylase
Related Products	Betulin TVB-3664 FT113 Fatostatin C75 C75 trans Desoxyrhaponticin trans-Chalcone IPI-9119 Eicosapentaenoic acid ethyl ester Fatty Acid Synthase Antibody [K9D22] Sodium palmitate Fatty Acid Synthase Antibody [K10B23] TVB-3166 Praeruptorin B SLC27A4 / FATP4 C-terminal Antibody [J15G12] Fasnall

Chemical Information, Storage & Stability

Molecular Weight	439.55	Formula	C₂₇H₂₉N₅O	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1399177-37-7	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	ASC-40, FASN-IN-2			Smiles	CC1=NN=C([NH]1)C2=C(C=C(C)C(=C2)C(=O)N3CCC(CC3)C4=CC=C(C=C4)C#N)C5CCC5

Solubility

In vitro
Batch:

DMSO : 88 mg/mL (200.2 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 88 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.400mg/ml (10.01mM)	Taking the 1 mL working solution as an example, add 50 μL 88 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	FAS ^[1]
In vitro	Denifanstat (TVB-2640) markedly inhibits SARS-CoV-2 with EC50s of 4 nM, and could strikingly inhibit SARS-CoV-2 new variants with similar inhibitory effects on the early-lineage SARS-CoV-2 (USA-WA1/2020) virus.^[2]
In vivo	Denifanstat (TVB-2640) shows significant in vivo antiviral activity and protects SARS-CoV-2-infected mice for survival.^[2]
References	[1] https://pubmed.ncbi.nlm.nih.gov/31630414/ [2] https://pubmed.ncbi.nlm.nih.gov/34580494/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05743621	Recruiting	Prostatic Neoplasms Castration-Resistant	Weill Medical College of Cornell University\|Sagimet Biosciences Inc.	November 20 2023	Phase 1
NCT05835180	Completed	Non-alcoholic Steatohepatitis\|Hepatic Impairment\|Cirrhosis	Sagimet Biosciences Inc.	May 1 2023	Phase 1
NCT05657834	Completed	Healthy Volunteers	Sagimet Biosciences Inc.	November 21 2022	Phase 1
NCT04906421	Completed	Nonalcoholic Fatty Liver Disease	Sagimet Biosciences Inc.	August 12 2021	Phase 2
NCT04843449	Completed	Healthy	Ascletis Pharmaceuticals Co. Ltd.	April 4 2021	Phase 1
NCT04352361	Completed	Healthy	Ascletis Pharmaceuticals Co. Ltd.	April 2 2020	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):